Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 14Neoplasm Metastasis 5Liver Neoplasms 4Leiomyoma 3Uveal Melanoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Stomach Neoplasms 1Spinal Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Myoma 1Desmoid Tumors 1Colorectal Cancer Liver Metastases (CRLM) 1Chylous Ascites 1Cholangiocarcinoma 1Blood Loss, Surgical 1Abdominal Neoplasms 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Embolization, Therapeutic × Clear all
NCT02587884 2016-03-31

Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH

Eastern Hepatobiliary Surgery Hospital

Phase 1 Unknown
180 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡